ArticleScientific reports2025
Genome-wide iterative fine-mapping for non-Gaussian phenotypes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative fine-mapping of breast cancer susceptibility loci using summary statistics methods and multinomial regression.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fine-mapping seeks to identify causal variants associated to a phenotype of interest. Fine-mapping searches through genomic regions previously identified by single marker analysis of genome-wide association studies (GWAS) data. This two-stage approach (1) often fails to identify causal variants with smaller effect sizes, and (2) does not properly correct for multiple comparisons. The former problem leads fine-mapping to have low recall of causal genetic variants, and the latter problem leads to high false discovery rate (FDR). To address these issues, we propose a novel Genome-wide Iterative fiNe-mApping method for non-Gaussian data (GINA-X). GINA-X efficiently extracts information from GWAS data by iterating a screening step and a variable selection step. The screening step provides a list of candidate genetic variants and an estimate of the proportion of null genetic variants. After that, the variable selection step selects a more focused list of genetic variants using the estimated null proportion to appropriately control for genome-wide multiplicity. A simulation study shows that, when compared to competing fine-mapping methods, GINA-X reduces FDR and increases recall. Case studies on alcohol use disorder and breast cancer show that GINA-X provides more focused lists of candidate causal genetic variants with better predictive performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.